» Articles » PMID: 15455183

Relationships Between the Changes of Serum Levels of OPG and RANKL with Age, Menopause, Bone Biochemical Markers and Bone Mineral Density in Chinese Women Aged 20-75

Overview
Specialty Pathology
Date 2004 Sep 30
PMID 15455183
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The correlations between the serum levels of OPG, RANKL with age, menopause, bone markers, and bone mineral densities (BMDs) at the lumbar spine and proximal femur were studied in 504 pre- and postmenopausal Chinese women aged 20-75 years. We found that age was positively and negatively correlated with serum concentrations of OPG (r = 0.442, P < 0.001) and RANKL (r = -0.263, P < 0.001), respectively. Compared with premenopausal women, postmenopausal women showed higher serum OPG levels (107.6 +/- 3.0 vs 72.0 +/- 1.8 pg/ml, P < 0.001), lower serum RANKL concentrations (4.7 +/- 0.4 vs. 5.8 +/- 0.3 pg/ml, P < 0.001) and RANKL/OPG ratios (0.045 +/- 0. 004 vs. 0.099 +/- 0.008, P < 0.001). Neither serum levels of OPG nor RANKL or RANKL/OPG ratio correlated with BMDs after adjustment of age and menopause. They also showed no differences among normal, osteopenic and osteoporotic postmenopausal women. Serum levels of OPG were positively correlated with urinary excretion of NTx (r = 0.1453, P = 0.006). Serum levels of RANKL (r = -0.1928, P < 0.001) and RANKL/OPG ratio (r = -0.1303, P = 0.013) were inversely correlated with serum concentrations of OC. In multiple regression analysis, up to 20% variance (R(2) = 0.106-0.224) of the OPG-RANKL system in peripheral circulation can be explained by age, menopause and bone markers. These results suggest that although serum OPG and RANKL concentrations were unrelated with BMDs, the age- and menopause- dependent changes of serum OPG and RANKL might be a protective mechanism against the accelerated bone loss in postmenopausal women.

Citing Articles

Assessment of the concentration of osteoprotegerin and receptor activator of nuclear factor kB ligand in healthy children.

Adamiecka P, Chlebna-Sokol D, Jakubowska-Pietkiewicz E Pediatr Endocrinol Diabetes Metab. 2025; 30(4):183-189.

PMID: 39963055 PMC: 11809546. DOI: 10.5114/pedm.2024.146681.


Delineating the relationship between circulating osteoprotegerin and bone health in women with a pathogenic variant in : A cross-sectional analysis.

Mokhber A, Hall E, Uzelac A, Salmena L, Cheung A, Lubinski J Bone Rep. 2024; 22:101802.

PMID: 39297019 PMC: 11408939. DOI: 10.1016/j.bonr.2024.101802.


Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study.

Amer O, Wani K, Ansari M, Alnaami A, Aljohani N, Abdi S Medicina (Kaunas). 2022; 58(8).

PMID: 35893092 PMC: 9330386. DOI: 10.3390/medicina58080976.


Chitosan Scaffold Containing Periostin Enhances Sternum Bone Healing and Decreases Serum Level of TNF-α and IL-6 after Sternotomy in Rat.

Salehiamin M, Toolee H, Azami M, Ahmadi Tafti S, Mojaverrostami S, Halimi S Tissue Eng Regen Med. 2022; 19(4):839-852.

PMID: 35199306 PMC: 9294132. DOI: 10.1007/s13770-022-00434-8.


The cross-talk between matrix metalloproteinase-9, RANKL/OPG system and cardiovascular risk factors in ovariectomized rat model of postmenopausal osteoporosis.

Sabry M, Mostafa S, Kamar S, Rashed L, Estaphan S PLoS One. 2021; 16(10):e0258254.

PMID: 34610044 PMC: 8491879. DOI: 10.1371/journal.pone.0258254.